Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -282,089 | -203,780 | -122,523 | -61,933 | -159,429 |
| Depreciation Amortization | 19,553 | 12,156 | 5,545 | 1,731 | 272 |
| Accounts receivable | -1,736 | -2,492 | -49 | 0 | 27,000 |
| Accounts payable and accrued liabilities | 4,425 | 147 | -1,099 | 789 | -360 |
| Other Working Capital | 39,972 | 39,204 | 31,155 | -1,186 | 34,272 |
| Other Operating Activity | 41,373 | 38,577 | 26,469 | 17,310 | -7,916 |
| Operating Cash Flow | $-178,502 | $-116,188 | $-60,502 | $-43,289 | $-106,161 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4,098 | -1,890 | -1,113 | -539 | -3,230 |
| Net Acquisitions | -818 | -818 | N/A | N/A | N/A |
| Purchase Of Investment | -259,304 | -239,821 | -159,412 | -159,412 | -331,362 |
| Sale Of Investment | 276,469 | 263,469 | 148,969 | 54,500 | 317,000 |
| Purchase Sale Intangibles | -118 | -118 | -118 | -118 | N/A |
| Other Investing Activity | -118 | -118 | -118 | -118 | 0 |
| Investing Cash Flow | $12,131 | $20,822 | $-11,674 | $-105,569 | $-17,592 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 287,500 | 287,500 | 287,500 | 287,500 | N/A |
| Common Stock Issued | 90,840 | 21,057 | 17,251 | 16,153 | 223,777 |
| Other Financing Activity | -46,856 | -44,397 | -39,904 | -39,306 | -2,120 |
| Financing Cash Flow | $331,484 | $264,160 | $264,847 | $264,347 | $221,657 |
| Beginning Cash Position | 171,890 | 171,890 | 171,890 | 171,890 | 73,986 |
| End Cash Position | 337,003 | 340,684 | 364,561 | 287,379 | 171,890 |
| Net Cash Flow | $165,113 | $168,794 | $192,671 | $115,489 | $97,904 |
| Free Cash Flow | |||||
| Operating Cash Flow | -178,502 | -116,188 | -60,502 | -43,289 | -106,161 |
| Capital Expenditure | -4,098 | -1,890 | -1,113 | -539 | -3,230 |
| Free Cash Flow | -182,600 | -118,078 | -61,615 | -43,828 | -109,391 |